- Home
- AZN vs MRK Comparison
AZN vs MRK Comparison
Compare AZN & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZN | MRK |
|---|---|---|
| Founded | 1992 | 2000 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.7B | 268.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AZN | MRK |
|---|---|---|
| Price | $208.86 | $121.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $121.00 |
| AVG Volume (30 Days) | 1.6M | ★ 13.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 1.51% | ★ 2.81% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.84 | $3.66 |
| Revenue Next Year | $6.16 | $5.28 |
| P/E Ratio | $32.35 | ★ $16.62 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $122.26 | $73.31 |
| 52 Week High | $212.19 | $123.33 |
Technical Indicators
Market Signals| Indicator | AZN | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 87.12 | 69.34 |
| Support Level | $187.06 | $116.10 |
| Resistance Level | $193.97 | $123.33 |
| Average True Range (ATR) | 4.23 | 3.26 |
| MACD | 4.29 | 0.37 |
| Stochastic Oscillator | 96.80 | 88.42 |
Price Performance
Historical ComparisonAbout AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).